Pfizer protects $6.4bn heart disease blockbuster from generics, for now [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
In a statement, Pfizer said it has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, all of whom were planning to market generics of its medication used to treat cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). The settlements, which end lawsuits filed by Pfizer alleging patent infringement, push back the US patent expiry for Vyndamax to 2031, though this is pending the outcome of other litigation. Pfizer's chief US commercial officer, Aamir Malik, said: "We are very pleased by this outcome, both for patients and in recognition of the value of our innovative science and the strength of our patents.” Pfizer's tafamidis franchise, which comprises of both Vyndamax and Vyndaqel, generated $6.38bn in 2025, up 17% from 2024. The big pharma company now only sells tafamidis as Vyndamax, after discontinuing Vyndaqel – the lower dose brand – at the end of 2025. Pfizer had previously forecast a significant decline in US Vyndamax sales upon loss of exclu
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Cryptococcosis Drugs Market Outlook 2026-2036 [Yahoo! Finance]Yahoo! Finance
- Global Pharmaceutical Market Poised to Surpass USD 3.2 Trillion by 2035 – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Pfizer (PFE) had its "neutral" rating reaffirmed by Citigroup Inc..MarketBeat
- Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple MyelomaBusiness Wire
- 2 High-Yielding Dividend Stocks to Buy for Passive Income in April [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- PFE's page on the SEC website